Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Stock Information for Stem Inc. Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Stem Inc. Class A

Sidoti Events, LLC's Year-End Virtual Investor Conference
Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.